tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lenz Therapeutics price target raised to $52 from $49 at Citi

Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $52 from $49 and keeps a Buy rating on the shares after the FDA approved Vizz a week earlier than the action date. The firm says Lenz has a week “head-start” to start commercialization of the drug.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1